ENGN

enGene Holdings Inc.

Healthcare
Biotechnology
$105M market cap

Forecast run · Oct 30, 2026Upside rank 155 of 3,167

Model Signal

ForecastQ Daily Probabilities

61.8%

37.0%

47.1%

Analyst Consensus

Recommendation2.78/5 Hold

Last price$1.56

Price target$3.00

Implied move+92.3%

Analysts9

ForecastQ Portfolios

ENGN is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.